SCHEMBL857124

SCHEMBL857124

C[C@H]1CCCC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22708 1.00
SCHEMBL38785 1.00
Water SCHEMBL28084183 0.97
Cyclohexanone SCHEMBL28845315 0.93 ALDH1A1 (0.50)
SCHEMBL14066006 0.92
SCHEMBL105656 0.92
SCHEMBL9490715 0.91 TRIM24 (0.38)
SCHEMBL24304032 0.90 KMT2A (0.54)
SCHEMBL2196645 0.90 KMT2A (0.54)
SCHEMBL230871 0.90 KMT2A (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743085-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4723887-A1 METHODS AND COMPOUNDS University of Leicester (GB) 2026-04-15 EP disclosed
EP-4695231-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2026-02-18 EP disclosed
US-20260043010-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2026-02-12 US disclosed
US-20250361234-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS INC (US) 2025-11-27 US disclosed
US-12371674-B2 Enone reductases CODEXIS, INC. (US) 2025-07-29 US disclosed
US-12358887-B2 IKAROS Zinc Finger Family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2025-05-29 US disclosed
EP-4536637-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2025054368-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed
US-6562807-B2 For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity NOVO NORDISK A/S (DK) 2003-05-13 US disclosed
EP-1296942-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS Novo Nordisk A/S (DK) 2003-04-02 EP disclosed
US-6465664-B1 CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-10-15 US disclosed
US-20020143186-A1 Glucagon antagonists/inverse agonists PFIZER INC 2002-10-03 US disclosed
WO-2002000612-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
WO-2001019761-A2 ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-03-22 WO disclosed
US-5440062-A One-(substituted)amino-7-(substituted)imino-1,3,5-cycloheptatriene-metal complexes as catalysts MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-08-08 US disclosed
US-5162586-A Catalyst complex containing copper, a disubstituted aminetroponeimine chelating ligand and an organometallic reagent MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1992-11-10 US disclosed
US-4962214-A COPPER AMINOTROPONEIMINE COMPLEX CATALYSTS MASSACHUSETTES INSTITUTE OF TECHNOLOGY (US) 1990-10-09 US disclosed
WO-1989010916-A1 ENANTIOSELECTIVE ADDITION OF HYDROCARBONS TO ALPHA,BETA-UNSATURATED CARBONYL COMPOUNDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-11-16 WO disclosed